Is Apple the Teflon Tech Stock? And the Latest Moves in the Weight Loss Drug Space 6/26/23

26 Jun 2023 · 44 min

Ask about this episode

Ask anything about it. ChatGPT or Claude reads this page and answers with the times it was said.

Connect VO and ask about every podcast you hear, including the moments you saved. Add to ChatGPT · Add to Claude

In short

Podcast Episode Notes: CNBC's "Fast Money" - Is Apple the Teflon Tech Stock? And the Latest Moves in the Weight Loss Drug Space (6/26/23)

Episode Overview In this episode, the panel discusses the resilience of Apple’s stock amidst a turbulent tech market, as well as the developments in the weight loss drug sector, particularly involving Eli Lilly and Pfizer. The discussion is led by Melissa Lee, joined by traders Karen Feinerman, Dan Nathan, Guy Adami, and Julie Beal.

Key Discussions

  1. Apple’s Market Performance
  2. Record Highs: Apple shares have reached new record highs, outperforming other tech stocks like Tesla and Nvidia which are seeing declines.
  3. Resilience: The panel questions whether Apple can maintain its performance despite broader market challenges.
  4. Passive Investing: Guy Dami mentions that Apple’s heavy presence in ETFs contributes to its price stability, receiving inflows as investors pull back from riskier tech stocks.
  5. Valuation Concerns:
  6. Current P/E ratio at 28x next year’s earnings with low EPS and revenue growth.
  7. Karen and Dan express concerns about Apple's high valuation compared to peers.
  1. Broader Market Implications
  2. Tech Sector Analysis:
  3. Multiple expansion in many tech stocks may not be sustainable.
  4. A potential sell-off could affect Apple eventually.
  5. Flight to Quality: Julie Beal suggests that Apple's perceived safety makes it a go-to stock in uncertain times.
  6. Geopolitical Risks: Concerns about potential disruptions in supply chains, particularly relating to China, are highlighted.
  1. Weight Loss Drug Developments
  2. Eli Lilly vs. Pfizer:
  3. Lilly announces positive results for its oral weight loss drug, showing nearly 15% weight loss over 36 weeks, which competes with Novo Nordisk’s offerings.
  4. Pfizer is exiting the weight loss drug market.
  5. Market Potential:
  6. Jeff Meacham from B of A Securities discusses the potential of these drugs being a $100 billion market opportunity, including impacts on various health conditions.
  7. The ease of administration with oral drugs may lead to increased market adoption compared to injectables, which may drive down costs.
  1. Investor Sentiment and Market Outlook
  2. Economic Concerns:
  3. The panel discusses recession risks and their influence on market performance, with some analysts forecasting a recession in the near term.
  4. Stuart Kaiser from Citi emphasizes the significance of growth broadening out to maintain investor interest in tech stocks.
  1. Final Thoughts and Predictions
  2. Short-Term Focus: Investors are advised to be cautious in the current environment, especially regarding the tech sector and weight loss drugs.
  3. Investment Strategies: Various recommendations are made for potential investments, with a focus on quality companies like Apple and emerging opportunities in pharmaceuticals.
  1. Closing Remarks
  2. The episode concludes with remarks on the importance of staying informed on market trends and the potential shifts within the tech and pharmaceutical sectors.

Key Takeaways

  • Apple’s Strength: While Apple's current stock performance is impressive, risks associated with high valuation and market fluctuations remain.
  • Weight Loss Industry Growth: The competition among weight loss drugs is intensifying, with significant market potential expected for oral medications.
  • Market Uncertainty: Investors should remain vigilant regarding economic outlooks and sector-specific risks, particularly in tech and healthcare.

Additional Resources

  • For more information, visit [Fast Money](http://fastmoney.cnbc.com) and listen to the full episode for detailed insights and expert analyses.

Written by AI. May contain mistakes. Listen to the episode to check what was said.

Hear the part that matters, and keep it.Open this episode in VO. Double tap your headphones to save a moment as you listen.
Get VO free

Transcript

Automatic transcript. May contain errors.

0:01Right now in Fast, a Google glitch. Shares of Alphabet taking a tumble after one analyst raise a red flag over the costs of AI, what the move says about the investment opportunities in the space. Plus, the weight loss wars heat up as Pfizer exits the ring and Lilly ups its game, how the primary players are positioned now and how you should play this sector. And later, rough scenes for Carnival, some clarity on Lucid's latest deal, and one big developer is moving out of Park Avenue. The stories and the trades behind the stocks are coming up. I'm Melissa Lee. This is Fast Money. We're live with the Nasdaq Market Site on the desk tonight.

0:31Karen Feinerman, Dan Nathan, Guy Adami and Julie Beal. We start off with the seemingly unstoppable Apple, the stock hitting a fresh record high during the session today, the third day in a row that it's done that. While the stock closed off the levels, it has risen as much as 3 percent, even after Jerome Powell seemed to take the wind out of the sails of the big tech trade in his congressional testimony last week. The same cannot be said for some of the other growth stocks, though. Tesla, for example, down nearly 13 percent for its Wednesday highs, and NVIDIA has shed almost 8 % in the last week.

1:02So we have asked this question before at least once, if not twice, or three times, or 10 times, or 20 times. Is Apple truly the Teflon stock? We will ask it again. Guy Dami, answer once again, please. Today, clearly it is. But historic. Go back five years. In 2018, since that point, you've seen probably six, if not seven, 25 to 40 % peak to trough decline. So Apple actually goes down at times as well. Apple is currently in, and don't at me if if I'm off by one, 354 ETFs, of which Apple is one of its top 15 holdings. So in the world of passive investing where money flows in, Apple's going to win to that.

1:40So it sort of makes sense that Apple continues to grind higher. Apple wins when people flee other high-growth tech names. The money flows into Apple. At a certain point, though, the musical chairs end in the no more chairs, and that's when Apple goes down. So it doesn't mean it's not a great company, but at 28 times next year's earnings with single-digit EPS growth, single-digit revenue growth, margins that are probably flatlining, if not declining, the stock is expensive here. You have lightened up, Karen. I have. I lightened up last week. Currently the day that was the all-time high, but I can guarantee you, as I said then, it will not be the all-time high if I lightened up.

2:16I promise that 100%. But I just feel like the whole space, meaning, you know, FANG, Big Cap Tech, has had huge runs. And the Apple, I actually have a little bit higher P.E. than you do on that. Remembering the hardware part of the business also, which has a lower P.E., so that means the rest of it trading at an even higher P.E. I don't know. I just felt like I got too much exposure overall. Apple to me is the one that I guess is, well, it's the most expensive with the exception now of NVIDIA, which is super expensive. But compared to a Meta or a Google, so I had to lighten. It's painful. But it did.

2:57Yeah. Yeah. I just say that. So Guy mentioned, you know, high single digits earnings growth, you know, mid to high single digits expected sales growth. So, you know, trading 10 turns over the S &P is multiple. It makes up seven and a half percent of the S &P. It makes up nearly 13 percent of the NASDAQ 100. And I think what's interesting to me is that we mentioned a couple other names that you said have been selling off over the last week that are truly expensive. They've seen multiple expansion on things that they haven't realized yet. a lot of excitement about technology that hopefully they will be able to harness over the next few years, clearly over the next decade or so, but they pulled forward a lot of excitement around.

3:29Apple's not in that situation. You know, if this AI thing hadn't happened in the last six months or so, we might have been really excited about spatial computing, about this new Vision Pro that they just launched at their WD, but we're not excited about it, and it's not in the stock right here. But something's in the stock, and maybe it's a flight to the sort of quality, Maybe because these 43 % gross margins have flatlined right there. And we found this sort of equilibrium between their hardware business, which makes up, let's say, two thirds of their revenue and the mixed shift with the services and all that sort of stuff.

3:59So, yes, it's Teflon because it seems to be very defensive, but it's trading in a multiple that it has not in a very long time. And that should make you a bit nervous, because if you see how money can come out very quickly of the most loved, exciting stories, ultimately, if we do have a sustained sell off, They will come for Apple because it will be an easy source of funds. Where do you stand on this, Julie? Because when they did come, you know, when Jerome Powell was very hawkish last week, when they came for the other tech stocks, they did not come for Apple. And so maybe Apple is, you know, the premium is justified and you want to pay up for it because it is safety, you know, in a time of uncertainty.

4:34It has been. It was during the bank crisis and it has been in the past week. A lot of it, I think, is a function, their ability to execute. They just have an uncanny ability to release products that people want. And I think we continue to see that going forward. The real challenge for them is where to find that next incremental$100 million of revenue that they can still generate at a high margin. And I think that's a real challenge for them. Here's a question, though. I mean, do they need to do that at this juncture in time? You know, because they will have new product launches. They've got this whole headset kind of thing going on.

5:15Do they need to do that right now, or can they just sort of wait because they are given the benefit of the doubt in this market environment right now? In terms of the stock price, I think they can wait. I mean, to me, there are a couple existential risks. The biggest one, obviously, is if things continue to heat up in China, China, Taiwan, obviously, specifically. And if that whole situation starts to rear itself in a worse way than it currently is, That could be a problem for Apple. But it's also a problem that the globe is slowing down. And at a certain point, consumers are going to stop spending on these products.

5:48We're not there yet, clearly, but we're going to get there. And Apple will not be impervious to that. You know, it's interesting. Some of the data we're seeing on consumers in China, in particular, of late is not great for Apple, especially when they've actually put up some decent quarters in China, you know, even as they were coming out of zero COVID or kind of into that sort of period. So those are things that, like, I think should be on your radar if you're invested in the name here, especially if you're thinking about adding to the position or it's a new position right here. And then the other issue, I mean, like Guy mentioned here, I mean, when you think about this company and their reliance on the supply chain in and around China, you know, reshoring, even if it's to other places that have cheaper labor than here in the U.S., it's going to be, you know, it's going to be a hit to their margins that have been, again, very stable.

6:33But those are the sorts of things that you want to start thinking about near a three trillion dollar market cap at a valuation that we have not seen in a very long time. How do you think about that? Because in the long run, that's that's the move to make reshoring. And yes, it's expensive in the near term, but it gives them more. I mean, if China is a political headwind or a potential tape bomb for China, it removes that. Right. At what cost, though? Right. I mean, who knows what cost? And so it's it's obviously a cost to them and it's a cost they have to pass on to the customers. And then it's, I would imagine, somewhat of an enormous endeavor from a supply chain cost just to how to get that up and running smoothly.

7:10And I would think you'd have to have duplicate manufacturing for a while. Although, if anyone can do it, they can. But just one other thing I want to point about Apple, a lot of people feel, well, it's got a great balance sheet. It does have a great balance sheet for sure. Yet, they do have some debt. You know, the amount of cash in their overall balance sheet is only 2 % of market cap now. 2%. Oh. It seems like an enormous amount. And it is a great balance sheet. They do generate tons of cash. What should it be? What percentage should that be in order for you to say it is a great balance sheet?

7:42Well, I look at something like Google with a great balance sheet, and their net cash is 6%. So I don't know. That's kind of a big difference. But is that a problem? Because they can go to the market. It's not a problem at all. They don't need money. You know, just that buying back stock has been a really great thing for them. They've made so much money for shareholders by doing that. It's just the perception of how much cash they have relative to the rest of their business seems a little. Yeah, but one point here is like if that debt to equity ever turned, okay, like debt to cash, that would be like a seminal event for a company that's actually bought back over a half a trillion dollars in stock since they instituted a buyback in 2012.

8:26And you think about this, we've been talking about a company for years that basically at best has had high single digits earnings growth per year. They have managed that massively through those buybacks. So, I mean, at some point, if they get on the wrong side of one of these big technological shifts or so, CapEx and R &D is going to have to ramp up. And let's just say they've made a mistake with spatial computing. Let's just say whatever they're spending, the billions and billions on this, is the wrong platform. And let's say they missed out on the auto or something in and around that. And that is the next 100, 200 billion dollars in revenue over the next decade or something like that.

9:03That's how companies like this see their dominance kind of go the way of the dodo. And as long as we've all been in the business, let's call it the last 30 years or so, there has not been a single tech company in that time period that has not been knocked off the pedestal in which they sat for a very long time. It just happened every single time. You know, you could say that some of us have been calling for that with Apple at every new product, you know, iteration or shift or something like that. At some point, it's going to happen. And those are the sorts of things that you want to keep an eye out for, in my opinion.

9:32When I just add one thing to that, the ecosystem that they do have, that embedded ecosystem with that cost of switching is really an extraordinary asset that it's not reflected in the balance sheet. Right. But I mean, you're an Apple guy. Yeah, you're an everything guy. You got all kinds of gadgets. But wouldn't it be hard to switch? Not really. I mean, to be honest with you, you know why? Because this is the story of China. So they have the everything apps. Right. So the hardware is less interesting to me. So like to me, I think at some point we probably do go that way. And when you think about India's population just crossing that of China's, they are not going to be spending on, you know, on the sort of hardware that like like the rest of the West or Europe spend on.

10:09So to me, I actually think there will be some sort of big shift in the next five to 10 years. But trying to trade that in Apple right now is probably hard. But Guy, what does this tell you about the market environment we are in, where Apple is continuing to make new highs almost every day, seemingly, at the expense of a lot of other tech companies? This is the part of the flight to quality, perceived quality. There's safety in Apple. We can be there. We can hide out there. We've seen this before, and it does end. And when it ends, it ends typically abruptly. Obviously, the broader market, I don't want to get too crazy here, but for the last week or so, it's starting to show at least some cracks out there.

10:42Apple probably wins to that. But a certain point in that timeline, they stopped winning to that. Now, we're not even close to that yet, but we've seen that before over the last couple of years. Well, today's NASDAQ weakness could be an opportunity for investors, according to our next guest. Citi listing big tech and growth stocks as top plays for at least the next six months. Let's bring in Stuart Kaiser, the firm's head of equity trading strategy. Stuart, great to have you here on set. Welcome. Great. Thanks for having me. So why at least the next six months? I mean, what about the environment?

11:10High interest rates, higher for longer spells big tech growth stocks to you? You know, I think the way we've been approaching the year is you've got very high cash yields. You've got recession risk kind of in the background. And that's the main driver of people wanting to be in large cap tech and growth stocks. Essentially, there's a scarcity of growth and people are willing to pay a premium to be in them. So from our perspective, the key to unlocking that trade is you need growth to broaden out, which effectively means recession risk come down. We still have a recession in our forecast. So in our view, that sort of overarching operating environment stays in place.

11:39And that should be relatively favorable to tech. I think the other thing is, yeah, there's a valuation aspect to this. But these are stocks that have stronger EPS momentum, have stronger revisions. There's a fundamental reason for this beyond just valuation. And you put that all together and we're still comfortable being in the space, though the risk reward isn't what it was a few months ago, clearly. You're a sector guy, so I'm not going to ask you specifically about an NVIDIA, let's say. But you do like that sort of AI momentum trade. How much of it are you worried about the valuations there in particular?

12:08I mean, AI, you can believe it's a real thing. You can believe that there's an investment cycle, but you may not believe that NVIDIA should be trading where it is. Look, stock by stock, yeah, there might be some stocks that look a little rich. We have about 35 AI winners in our quote unquote basket. The average or the median P on those stocks is actually down year to date because of the massive revisions to both EBITDA and sales. So, yeah, you could probably pick out a stock or two here where the valuation's got inexpensive. And that's why you diversify. You own kind of a basket of these stocks.

12:35And our view on AI is the revenue revisions been better to the market, been better than peers. The EBITDA revision has been better than the market, been better than peers. Valuation hasn't gone crazy. Frankly, what worries us the most is a little bit of fatigue in the sector. We are starting to see long-only flows kind of calm down into that space. So while we do like it medium term, we're kind of taking a pause here just to see how that flows dynamic pillies out a bit. Stuart, give us a sense. You just said you're starting to see some fatigue, and I think that was evident in some of these big names today.

13:01If enough big sellers head for the door at the same time, you get the sort of moves like we had in NVIDIA or Tesla. It doesn't really matter what the reason. What about complacency? I mean, I'm sure you have a lot of clients who spend time looking at things like the VIX or the VIX and that sort of thing. I mean, they're at levels that we have not seen since basically February 2020. Give us a sense for sentiment out there, at least in the flows that you guys are seeing. I think sentiment, you know, I wouldn't call it necessarily complacent. But, you know, I think, you know, people are becoming converts effectively.

13:27Right. I mean, you enter this year with very deep recession risk. Those have come out. So, you know, I don't know if I call complacency. I just think, you know, people have kind of risk adjusted how they're looking at things. I would say, even though the VIX is low, if you look at the shape of the VIX term structure, you go out three or five months, and the VIX is still at quite high level. So I really think what the market has done is said near term, maybe the risks have come in. We still think there's a considerable amount of medium term risks out there. And that's kind of where the risk is priced.

13:52Obviously, as you get closer to that, people get a little more concerned, and you see people lightening up. So, look, I think people are still hedging. People are still being very careful. And I do think there is risk premium price. It's just not priced in the next kind of two to four weeks at this point. At least the next six months seems like a very specific sort of time frame. So why the next six months and what happens beyond that that makes it a little less clear? Well, part of this, we just have to put a number on it, of course. But I would say, look, you know, our economists have a recessionary quarter in the fourth quarter.

14:21So I think up until you get to that recession data kind of being in front of you, we think people are going to be pretty conservative. A lot of people operate under this rule of thumb that you buy cyclicals when you're in the recession. Right. So six months would take us, in our view, kind of to the edge of that recession. And then you have to reevaluate, right? You need to see what the growth data looks like. How deep does this recession look like? It might be. How long might it last? And I think at that point, you have a lot of big decisions to make in terms of allocation. But until we see that, you know, that dot on the horizon become a line or something like that, you know, we're going to be pretty careful with the with the allocations.

14:52So let me ask you, if that dot on the horizon is a recession, it would seem to be likely then that we see a cut in interest rates, which has been a great ballast for these. How do you weigh those two things? Yeah, and if you look at 2024, there's about 150 basis points of cuts priced into 24. The markets kind of priced out the cuts that were in 2023. And I think that, frankly, just because the data has been stronger than it otherwise would have been. I think this is a big debate. You know, are rate cuts good or bad for markets? In our view right now, they'd actually be bad for markets because I think if the Fed is forced to cut, it's not for good reasons.

15:25It's because growth data is deteriorating at a pace you're not comfortable with. So I don't think you need rate cuts for the market to work. And frankly, I think if you started to price deeper rate cuts, you would be concerned about what the Fed's seeing from a growth perspective. What is a sector you absolutely do not want to be in for at least the next year? Look, I mean, people have voted with their feet on two sectors this year, and that's financials and energy. So those are probably, you know, two that we'd avoid a little bit. Energy in particular, I'm not an energy expert, but when the Saudis cut production and oil prices don't go up, I get a little bit suspicious.

15:56So I think those are the two areas that have been unloved by institutional investors on a year to date basis. And, you know, being that we think the investment environment is going to be pretty stable going forward, I think those are areas where we're not particularly excited by at this point. Stuart, great to have you. Thank you. Thank you. Stuart Kaiser of Citi. Julie Beal, what do you think? Well, I mean, it's such a fascinating time period right now. If you think about it, all of us came into this year assuming there would be a recession in the coming weeks. I mean, the Fed was practically hanging out bingo cards for what's going on in the next recession.

16:26And it hasn't shown up. It hasn't materialized. And I keep wondering what is going to be the thing that tips us into it. Initially, I think everyone thought it could be, you know, what happened with SVB. And I think we continue to have concerns about what's going on in the shadow banking crisis looming ahead of us. But other than that, it's really hard to see what's going to kind of trip it into recession. So that's the part that I'm the most curious about right now. It's an impressive array of ribbons behind Julie, that third place ribbon. Very decorated, that Julie B. It's critical. Sorry, Julie.

16:59No, listen, I'll be serious for a second. I agree with him in terms of banks. I think banks have, there's some problems here. The bank stocks do not trade particularly well. I'll push back a little bit on energy. I understand the underlying commodity not being all that buoyant. I think the stocks are actually relatively cheap in this environment. All right, coming up, Alphabet's AI implications, what analysts are saying the trend could mean for long-term results. The details on that call next, plus some fast movers catching our traders' eyes today. Carnival and Las Vegas Sands heading in opposite directions.

17:28a dive into cruises and casinos ahead. Don't go anywhere. Fast Money is back in tune.

17:42Welcome back to Fast Money. A downgrade on Alphabet nabbing our call of the day. Trophy. Shares slipping more than 3 % after UBS says it sees limited upside ahead in the search engine shift toward AI and the potential impact it could have on the valuable ad real estate in the near term. This is really interesting. Downgrading to a neutral, upping its price target, though, to 132. That's about 11 percent higher than today's close. What do you make of that? We all knew that it's a push pull in terms of AI. Short term, it could be pressure on margins, but longer term, it could be amazing. What do you think?

18:15Well, it's an odd sort of I couldn't quite tell what what was going on there. It's higher price target, downgrade to neutral, a little bit higher than where we are. Okay. I think that, you know, clearly the rebound in Alphabet since that disastrous foray into the public, you know, introduction of their AI, which was so much further along and has been so important to them for so long. So they handled that better. I still think just on evaluation basis that Google is so much more attractive than the other FAANGs, some of the other AI plays, it's so much cheaper than Microsoft. So could it trade down?

18:54Absolutely. I mean, you don't want to see Bing taking market share. That won't be a great thing. But it's not all bad for Google, right? And the amount of computing that people will need, what their cloud business can do, how it can grow. I understand there's costs with that as well. But I see it as it's opportunity and cost both at not a crazy price. And Microsoft's price for the same kind of thing is much higher. The other point that the analyst is making, Julie, was that, you know, even if there are gains because of AI in terms of revenue, there's also an investment cycle, a spending cycle that is happening.

19:29And so they'll be spending a lot more money just to keep up with AI. What's your take here on this? Because from the beginning, you've been sort of questioning what the impact would be on its business model. Well, you know, a lot of people first were concerned that this was an existential threat, right? Because if search suddenly gets very good, it's going to be harder for them to generate a lot of revenue from that. And I think people have kind of come to terms with that challenge. The thing is, is Google has done a really great job in terms of getting its cost structure back in line with where it probably needs to be.

20:00And the level of profitability that it has, its ability to take on the investment required for AI is substantial. It's just much better position than everyone else. And if you think of all the hype that Microsoft has gotten for Bing and its moved market share, not one iota, really, it really tells you the strength of the franchise that Google has. Its biggest problem really is regulatory more than anything else. Yeah, no, and I think that is 100 % correct. And when you think about a downgrade like this, it's really kind of quizzical on a valuation basis when you look at how much multiple expansion has been assigned to, let's say, a Microsoft, when I don't think that anyone thinks that there's going to be some renaissance for Bing.

20:41And think about what Microsoft had to do. They had to invest like$12 billion in open AI just to get access to this sort of technology right now. And that doesn't even cost, like the cost to compute, all this stuff is going up. So to me, I think Google, while yes, they are going to have some competition from meta, from really from everybody, if you think about it. Ultimately, I think they'll probably have the best product. Their product will evolve and really open up a lot of other avenues and other businesses, especially as it relates to Google Cloud. So to me, this one back at 110 or lower, it seems like that's how you want to play AI over a decade because it's not just making a bet on this.

21:19This is the company's evolution. They've mapped this out over the last seven years anyway. It's interesting. I mean, there are a number of reasons to downgrade evaluation. I mean, trades in a market multiple, probably mid-teen CPS growth. So there are a lot of things to like about the stock. Technically, you could say, you know what, maybe it's run its course in the short term. This stock made an all-time high, I think, November of 2021. That recent low of 83 bucks or so. This moved to, what, 115, 118 or so. It's a 50 % retracement, almost to the penny, as Carter would say, of that range. So it makes sense that we take a pause here.

Read the full transcript

21:50But on valuation, I don't necessarily agree with that. All right. There's a lot more Fast Money to come. Here's what's coming up next. Cruises and casinos. Boats and bets. Shares of Carnival and Las Vegas Sands both making moves today. We're digging into those trades next. Plus, the weight loss wars continue. One pharma company slimming down and another bulking up on obesity drugs. How the stocks are shaping up ahead. You're watching Fast Money, live from the NASDAQ market site in Times Square. We're back right after this.

22:38Why are you laughing? This is not funny. Because in the breaks. We're going to talk about a buzzkill. This is not funny for Carnival shareholders. I apologize. It's not. The shares are 7.5 % despite reporting better than expected Q2 results before the bell. We have conversations during the break and sometimes they spill over. That's the explanation. The company is seeing strong demand heading into the summer season, but conservative earnings guidance weighing on the stock shares seeing their worst day since last November. I mean, the stock is basically a double year to date. A double year to date, guys.

23:07Which is why this move makes, I mean, put up a longer term chart if we could of the stock. It doesn't look particularly great. Over the last six months, it looks extraordinary. But it's been a declining chart. Quite frankly, the business is probably in a decline as well. So the move lower makes sense. There'll be an opportunity to buy the stock again. As a matter of fact, Dan Nathan just showed me a chart. It probably comes in around 13.5 to 13.75, but we're not there yet. And with a stock like this, I think you have to be that precise. They have$7.5 billion of debt coming due by 2025. They have a total amount of debt of more than$30 billion, Karen, which is hard to swallow in this interest rate environment.

23:49It is, although people seem to still be loving to go. They have some time. They do have the maturity spread out. Well, I don't follow this closely, but one thing from the notes someone can explain to me, they had 107 percent occupancy, which I don't know what that means. Have you seen those boats? Is that a stowaway thing? I mean, like the beach deck chairs or something. So I don't know what that means. That sounds like a good number. I don't know. So, I mean, I would have thought, actually, that we would have seen something lower than 107%. I don't know what it was. Like 100? Like 100, which is where they're going to, apparently, 100%.

24:33But good for them. I guess 100 is an actual occupancy. I don't know. But it's a great, great run. They're only back to where they were, you know, two weeks, less even. And it's just when things get so hot, I mean, the bar just got too high. I would love to know the answer to that. I wonder if you have people cancel. They pay and then they rebook to other people. And so it's more than more occupancy. OK. I don't know. OK. We'll get to the bottom of it. And we'll broadcast that answer. In the meantime, let's get to Las Vegas. I'm stopping the tape today, jumping more than a percent. JP Morgan reaffirming its overweight rating on the stock, also raising its price target by a buck, a dollar, excuse me, to$72.

25:11Guy, this screams Guy Dami. Yeah, it does. And listen, valuation, you can make a compelling case for Las Vegas Sands and win. And they obviously, you know, as China's obviously been somewhat deteriorating, they throw money at their economy. It doesn't seem to be working. These stocks have sort of felt that impact. But you got to like them on valuation. So I think if you can wrap your head around a slowing global economy, but understand that it's probably still priced in in terms of the valuation, I think you can own both win in Las Vegas stands here. Julie? It's not for me. I think you have to have such confidence in the outcomes in the Chinese market.

25:44And I don't right now. I think it's, you know, to be determined whether they continue to be as strong as they would like them to be. It sounds like the government is getting more and more nervous about the health of the consumer. Yeah. I mean, Dan, you're mentioning numbers that are coming. I mean, over the week, the Dragon Boat Festival, people weren't spending nearly as much as analysts had thought. And that's just not a question for Las Vegas Sands or Wynn or anybody else operating there, but just consumer products in general, too. Yeah, and it's interesting when you think about some of their exposure here in Vegas.

26:15I mean, like it sounds like things are pretty good there. But I think some of the corporate behavior and some of the travel and some of the, you know, the big, you know, goings on that used to be there. That's kind of been tamped down. That's kind of a post-pandemic thing. So, again, you know, here's a sector that's always traded at a massive discount to many of its kind of consumer oriented peers in the broad market. And I suspect given all the uncertainty both internationally and here, it continues to trade that way. Coming up, battle of the weight loss drugs. The gap is closing between Eli Lilly and Novo Nordisk.

26:43Who will take the lead? We've got more on that next. And New Kid on the Block, New York City's largest office landlord, selling a stake in one hot location. What that could mean for the Big Apple's real estate market. Back in two. Get your trades to go with the Fast Money Podcast. Catch us anytime, anywhere. Follow today on your favorite podcasting app. We're back right after this.

27:12Welcome back to Fast Money. Stocks closing lower to kick off the final trading week of the first half. The Dow dropping more than 1%, but the index still on pace for its best first half since 1983. The S &P down half a percent and the Dow virtually flat, now on a six-day losing streak. Slewis stocks closing lower after hitting all-time highs during the session. Among those names, homebuilders, DR Horton, Pulte Group, Palo Alto Networks, and Apple. And Eli Lilly also hitting a record earlier in the session. Speaking of Lilly, the drugmaker announcing positive results for its oral weight loss pill.

27:42The company is saying the treatment led to nearly 15 percent weight loss over 36 weeks. That is similar to Novo Nordic's rival treatment. But which of these companies will take the lead in the weight loss race? Let's bring in B of A Securities' Jeff Meacham to explain. Jeff, great to have you with us. I mean, it seems like an oral, it seems like a, you know, a pill would be really the holy grail. I mean, it's effective and it's really easy to take, really easy to comply with. That's right, Melissa. And thanks for having me, by the way. So, yeah, if you look at the data for, you know, for Lily's drug, the weight loss looks pretty impressive.

28:17There's still more work to do in phase three. So that's coming up. And I would say, you know, Novo's drug, Ribelsis, looked good enough, I think. But their profile could, I think, be a little bit more improved when you look at tolerability. Is it lower cost to manufacture the pill, do you think? And will consumers actually benefit or no? You know, it's a good question. I would view the orals. We've done a lot of expert work here. The orals, I think, will be definitely viewed as a drug for the masses, so to speak. But for patients that need a lot more efficacy, like Manjaro, like YGovie and like Triple G, there are other drugs out there that could be used in higher BMI patients.

29:02But for sure, though, you know, orals, I think, you know, would be higher margin, maybe easier to manufacture. It's Karen. Thanks for being on. So how do you think about the size of this market and where we are in that? How close? What is peak? What do you think peak is? You know, Karen, we're on record saying that these drugs are that Manjaro itself could be close to a hundred billion dollar of an opportunity, not just talking about, you know, diabetes and obesity, but including all the studies that Lilly is working on. So sleep apnea, prediabetes, chronic kidney disease, liver disease, et cetera.

29:37But officially, though, you know, our numbers are a little bit higher than consensus at the end of the decade and just obesity and diabetes. And that's about 40. So that's not that's not a trivial number. Jeff, I'm curious what your thoughts are in terms of, you know, how people will be staying on these drugs. We've heard so many stories about people going on a Zempic and then needing to stay on and having weight rebounds. Do you think that's the case? And is that how they're building out their models? Yeah, it's a great question. You know, there's a different there's different type of strategy for this.

30:10So for sure, some of the drugs that are more efficacious, you know, 20, 25 percent, unlikely that patients are on for years and years. My guess is that, you know, say six to 12 months on that, then they'll go off, take some sort of drug holiday and eventually come back because the vast majority of patients actually gain the weight back. But an oral, though, could have a little bit more continuity. But those the oral is less effective. So 10 to 15 percent versus, say, 25 plus. You know, but my guess here is that a lot of it will depend on how how accessible the drugs are from payers and insurance companies, et cetera.

30:50Um, you're clearly a little bit more optimistic than, than your counterparts on Wall Street when it comes to specifically Monjaro. And I'm thinking, I'm just wondering, Jeff, if you're starting to think about the, um, the sort of ancillary impacts, I mean, if, if all these people are losing weight and reducing the risk for other sort of, you know, heart disease, high blood pressure, et cetera, what that does to other pipelines? Yeah, no, it's a great question. You know, if you look at the, the benefits of these, these obesity drugs, the savings to the health care system could really be really, really pronounced.

31:22But we have to have broad access to them. So my guess is that we'll need, you know, cardiovascular outcomes data that further support the profile. We'll need maybe some pharmacoeconomic analyses. But in general, though, I would say in the near term, the costs will be driven by the drug. The economic benefits will be driven in the outer years. But for sure, though, it's not just about weight. You know, these drugs could also lower lipids. They lowered, you know, blood sugar, obviously. They lower blood pressure. So there's a there's a it's more than just the weight loss. That's the headline. Economic benefits to the insurers, economic benefits to consumers.

32:04That spells to me pain for some of the pharma companies. And I'm wondering, you know, a lot of these drugs are probably off patent already. So they're not big moneymakers necessarily. But should we start thinking about that? You know, so Manjaro from Lilly has just approved last year in type 2 diabetes and have some off-label use in obesity and could be formally approved in obesity this fall. But the IP goes out quite a while. It's not until 2030, 2031 that the Inflation Reduction Act discounts start to play out there, though. So these are early cycle drugs, to be honest. obesity has been a holy grail type of market with many, many failures.

32:49And just in the past two years, have we seen some real step up in terms of innovation and efficacy? So you don't think there's any impact on other drug pipelines like cholesterol drugs, heart drugs, et cetera, until it's widespread adoption? A lot of those are generic. Yeah, that's right. That's right. You could have an indirect effect, though, on other parts of the, say, the diabetes continuum So, you know, the insulin market and a lot of the ancillary sort of, you know, products and services with that, sleep apnea, CPAP machines, things of that nature. If we get 20 percent plus weight loss across the board for a lot of these drugs, you'll see, you know, volumes decline for other, you know, let's say lower tech kind of categories in diabetes.

33:36Jeff, great to have you on the show. Thank you. Thank you. Yep. Jeff Meacham. Guy, what do you think? Lots to like about Eli Lilly. The reversal today is not great. It's one day I want to make a big deal out of it. But, you know, they've I think they just recently surpassed Johnson & Johnson for market cap. I think Eli Lilly is probably close to four and forty billion dollars in market cap. And what's going to line up here is it's going to be a half a trillion dollar company, in my opinion, along with a five hundred dollar stock price. They'll split five for one. People will get geeked up. And their total addressable market in this space alone means they could probably double EPS over the next couple of years, which makes a valuation that seems rich now not nearly as, I think, scary for people.

34:15Yeah, and when you listen to him, he said it could be a$100 billion market. And that, you know, just when we started covering this story like five months ago or something, and then it was like maybe$50 billion or something like that. When you think of the split screen that we had over the weekend between the story about Lilly's trials with his oral and Novo's and then Pfizer this morning, it's pretty amazing. Novo and Lilly are both$30 billion revenue companies. And to Guy's point, they're going to get a lot of the EPS benefit, especially if it is$100 billion. And this oral thing is a game changer.

34:43I just think, again, it's going to drive down the cost of the drug, and it's going to make it that much more accessible over the next couple of years once it does get a price. Will it drive down the cost, though? Yeah, it should do. Okay. I don't know. It's very expensive to actually make the injectable and deliver the injectable. It needs to be put in cold storage and all that sort of stuff. So it's just going to be a lot easier across the whole supply chain. Yeah. What do you think of the valuations here? I mean, if if one drug is one hundred billion dollars. Yeah, well, the game, it does change the game.

35:14Getting there, though, in a few years, I mean, it's you know, I sold Lily way too soon and Novo as well. And then Pfizer, Pfizer did have one drug that they're going to stick with. But it's yes, a pill, which I feel like we don't know who else is out there yet. I think I mean, obviously, this is the holy grail. So I don't think people leave it at that. OK, Phil, you know, Lily got it. Right. Right. So I got out too soon. I guess that if I owned it now, I probably would sell it. What does that tell you? You're not buying it now. Well, that's what tells me what I should do. All right. Coming up.

35:50Luxury EV is the deal that had shares of Lucid rising today. And options traders are plugging in next. And throughout June, CNBC is celebrating Pride Month. Here's the head of Bank of America's digital team.

36:03you never know what someone experienced that morning before they showed up to work or what they're dealing with in their personal life so when we all show up to work we should do so with grace and with compassion for one another even now in 2023 the struggle for our lgbtq plus teammates family members and friends continues to be very real it's important to take a moment during Pride Month, but frankly, all year round to celebrate the victories and show our support for the ongoing struggle.

36:41It's a hugely exciting deal where we have a technology supply partnership, a true long-term partnership between Lucid and Aston Martin, where Lucid's technology is going to propel Aston Martin into a new era of electrification. And for us, it's a validation point of the supremacy of our technology. That was Lucid CEO Peter Rawlinson on closing bill overtime earlier today. Shares of the EV maker rising as much as 15 % today after announced it will provide powertrain and battery systems to British luxury car company Aston Martin. Stock finishing well off its highs, but option traders are betting on big gains ahead for Lucid.

37:25Mike Co's got the action, Mike. Yeah, Lucid was one of the busiest single stocks today, 11th busiest, actually traded more than three times its average daily call volume. And the busiest contract were the weekly six strike calls. We saw just under 50 ,000 of those trade for about a quarter of contract. Buyers are obviously betting that the slight bump we saw today could actually accelerate by the end of the week. But I would also point out this is a stock with a fairly substantial short interest, and it's obviously seen a big decline. So some of this could also just be expecting some kind of a rebound.

37:57Yeah. Guy, what did you make of this move? It should have been a bigger move, quite frankly. I mean, we're talking about a stock that recently made a multi-year low at 545 or something. I mean, the bounce was somewhat anemic. Now, people are going to be playing for a huge percentage bounce. I think it'll be short-lived, although I love Coco Beware on that great Friday night show at 530. What do they call it? Options action. Tune in. It's only been on for more than a decade, well more than a decade at this point. Mike, thank you. Mike Coe, for more options action, be sure to tune into the full show.

38:28That's Friday, 530 p.m. Eastern Time. Coming up, talk about being in the green. New York City's largest office landlord surging after offloading a major piece of real estate. What the deal could mean for the office-based sector ahead. Fast Money's back in two.

38:45Welcome back to Fast Money. Shares of New York's largest corporate landlord, S.L. Green, soaring today after selling its 49.9 % stake in a prime Manhattan office building. The deal for 245 Park Avenue coming at a$2 billion valuation provides a major boost to New York's struggling corporate real estate market. Karen, you're following this very closely. Yes. I mean, so there's signs of life here, maybe. So that's this is a it's a very good property. It was a decent price. And so if we start to see transactions, then we'll start to see companies improve their balance sheet like SL Green. They've got a ton of debt.

39:20So there's a lot of sort of turbocharged to the equity when they're able to help their balance sheet and get more life. Right. So I think we'll see that again and again. If we start to see it more, it sort of begets more. And then also we start to see some financing markets open, which is really important to them. We did see Boston Properties do a bond deal in May, but they are sort of the cream of the crop. They may be the only one who was able to do that at that time. Any transactions are good. Yeah. We talked to Jonathan Litt of Landed Buildings, and he often cites cell phone data. And in New York City, the cell phone data has not been so bad, better on a relative basis than some other cities.

39:59San Francisco is a disaster. Exactly. Exactly. But this I mean, so even with that, this deal is it's not seen as sort of like this is an exception because this this market is a premium. I mean, it's still good for the overall sector. I think it is to great properties in in relatively strong markets. Well, they're priced like now any properties. It's not priced like a great property. And maybe we'll start to see some. I think San Francisco really is quite a disaster. I mean, it's extraordinary. But I think just any transactions and you see one, everyone's sort of waiting. Well, I'm going to wait till they get cheaper, cheaper.

40:34Well, now someone stepped in and that makes people think, well, OK, I need to step in. Yeah. Julie, your thoughts? Yeah, it's a pretty stagnant market right now. It's the same in the residential markets where everyone is kind of sitting on their hands. But we know that we have a lot of refinancing that has to happen. And so these transactions kind of help move things along because otherwise I worry a lot about future defaults on buildings in certain markets. I think New York is OK, but for sure, I agree there are other markets, not just San Francisco. Guy? Premium location. I think a lot of people are saying$700 a square foot was sort of the mean-ish.

41:11This went for north of$1 ,100 a square foot. So it's a good thing. But is this just a bounce in an oversold condition? That's what you have to come to grips with. So I think that's probably exactly what it is. Big volume day today. I wouldn't say faded necessarily, but short leash for sure on the long side. All right. Up next, final trade.

41:32Do not miss a brand new podcast hosted by our own Karen Fireman. How she does it launching today, a show about finding your power, building your place in the world and discovering what it means to truly make an impact. available on hermoney.com and on Apple Podcasts. Karen. Melissa. This is quite a journey for you. It has been quite a journey. So I've wanted to do this for a while. You know, I have these occasional women dinner parties, and I love them. I love meeting all these women who are in very different fields and learning about their careers, how they got there, what did they do to what sort of hardships did they overcome.

42:09None of them have a straight path. and I was very, very happy that my first guest was Melissa Lee, who I think, you know, someone I love, someone I love to talk to as well, and someone whose story I find so compelling. Not where you thought you'd end up, certainly not where your parents thought you'd end up, and yet, and yet, here you are. And I just, I feel like there's so many things to learn from women who've done different things, pivoted, changed, failed, picked themselves up again. One of our guests is Julie Wainwright, who is the CEO and founder of The Real Real, which I also learned about hardship there, but to hear her story of how she was unhirable and yet figured out, all right, I got to build my next job.

42:50And so I'm fascinated by these stories, and I hope other people like to listen to them too. I can't wait to listen to the rest of it. I am honored to be the first episode, so I hope you all will check it out. I know Guy and Dan are a big podcast store. Aside from their podcast, of course. Time for the final tray. Let's go around the horn. Julie. Julie. I'm looking at Google again. You know, you can own a nice monopoly right now and a call option on AI in the future. Karen. Julie, I love that trade. I have a different one. CVS, though, is my final trade the other day. I think it's just too cheap for all the businesses it has.

43:22It can help get space. Dan. Yeah, for all you oldies, just go to the podcast store. Smash the subscribe button. How she does it. That's it. Do it now. QQQ. I'm a seller. I think that's awesome. Great picture, by the way. Delta Airlines breaking out here. at Melms. Look at that. Nice call on that one. Thanks for watching Fast Money. We'll see you tomorrow at 5 o 'clock. Meantime, Mad Money with Jim Cramer starts right now.

43:48All opinions expressed by the Fast Money participants are solely their opinions and do not reflect the opinions of CNBC, NBC Universal, their parent company or affiliates, and may have been previously disseminated by them on television, radio, internet, or another medium. You should not treat any opinion expressed on this podcast as a specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion. Such opinions are based upon information the Fast Money participants consider reliable, but neither CNBC nor its affiliates and or subsidiaries warrant its completeness or accuracy, and it should not be relied upon as such.

44:22To view the full Fast Money disclaimer, please visit CNBC.com forward slash Fast Money disclaimer.

From the publisher

Shares of Apple touched another record high today, even as one-time high-fliers like Tesla and Nvidia give back recent gains. So why is the iPhone maker able to keep trucking higher? And what does its strength say about the rest of the market? Plus Eli Lilly getting some positive results for its oral weight loss treatment, while Pfizer abandons its efforts in the space. We dig in on the weight loss battle, and how the biggest players stack up.

 

Fast Money Disclaimer

 


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

More from CNBC's "Fast Money"

All 871 episodes
Is Apple the Teflon Tech Stock? And the Latest Moves in the Weight Loss Drug Space 6/26/23CNBC's "Fast Money" · 44 min
Listen in VO